Over the last decade, Grindeks has been focusing on its own brand portfolio, but under the new CEO we are shifting our business development strategy.
A detailed review of our manufacturing sites in Latvia, Estonia and Slovakia revealed that even within our 24/7 production units there is unused capacity and equipment with significant potential. Having worked with numerous CDMOs ourselves, we fully recognize the added value, flexibility, and speed they bring. Pharma collaborations are essential for companies navigating the full complexity of pharmaceutical development and manufacturing.
Grindeks now provides a wide range of development, analytical, and manufacturing services to support all stages of API and FDF development – from early research phases to full GMP production: https://grindeks.com/en/cdmo/
We also offer ready-to-file dossiers and marketing authorization packages suitable for EU and international markets: https://grindeks.com/en/products/grindekspharmaceuticaloutlicensing/
